Related Experiment Videos
First-trimester Down's syndrome screening using nuchal translucency: a prospective study in patients undergoing
B Brambati1, C Cislaghi, L Tului
1First Institute of Obstetrics and Gynecology, University of Milan, Italy.
Summary
Nuchal translucency thickness measurement effectively screens for fetal aneuploidies, including Down's syndrome, in early pregnancy. Higher accuracy was observed at 9-10 weeks and in private practice settings.
Area of Science:
- Maternal-Fetal Medicine
- Prenatal Diagnostics
- Medical Imaging Ultrasound
Background:
- Nuchal translucency (NT) measurement is a key first-trimester screening tool.
- Accurate NT assessment is crucial for predicting fetal chromosomal abnormalities.
Purpose of the Study:
- To prospectively evaluate the efficacy of NT thickness measurement in predicting fetal Down's syndrome and other aneuploidies.
- To compare screening performance across different gestational ages and clinical settings.
Main Methods:
- Prospective evaluation of 1819 pregnancies undergoing chorionic villus sampling.
- Standardized ultrasound approach and equipment used across National Health Service and private clinics.
- Analysis of NT thickness (≥3 mm vs. <3 mm) and its correlation with chromosomal aberrations.
Main Results:
- An NT thickness of ≥3 mm was associated with an 18.6% incidence of chromosomal aberration, versus 1.7% for <3 mm.
- Overall sensitivity, specificity, and relative risk for aneuploidy were 30%, 96%, and 10.83, respectively.
- Screening performance (sensitivity, specificity, relative risk) was significantly higher at 9-10 weeks gestation and in private practice patients.
Conclusions:
- NT thickness measurement is a valuable tool for first-trimester fetal aneuploidy screening.
- Gestational age (9-10 weeks) and clinical setting (private practice) significantly influence screening efficiency.
- Individual, structural, and organizational factors impact the overall effectiveness of ultrasound screening programs.